8JD.F VALBIOTIS S.A. EO -10
- Market cap
- EUR 20.3M
- P/E
- -
- P/B
- 1.68x
- ROE
- -135.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 8JD.F undervalued?
Graham numberThe Graham number of VALBIOTIS S.A. EO -10 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
VALBIOTIS S.A. EO -10 fundamental analysis
No fundamental analysis for VALBIOTIS S.A. EO -10 yet.
VALBIOTIS S.A. EO -10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About VALBIOTIS S.A. EO -10
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood p…
Full company profileVALBIOTIS S.A. EO -10 financial statements
VALBIOTIS S.A. EO -10 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 298K | 785K | 4.73M | 175K | 905K |
| Gross Profit | 282K | 767K | 2.67M | -2.44M | -1.32M |
| Operating Income | -8.48M | -12.0M | -7.18M | -10.4M | -9.50M |
| EBITDA | - | -11.2M | -6.41M | -9.18M | -8.96M |
| Net Income | -8.68M | -12.3M | -7.37M | -10.0M | -9.42M |
| EPS | -0.89 | -0.99 | -0.46 | -0.63 | -0.40 |
| Balance Sheet | |||||
| Total Assets | 28.5M | 27.2M | 33.3M | 19.6M | 14.4M |
| Total Liabilities | 14.2M | 13.9M | 13.7M | 9.24M | 7.43M |
| Shareholders' Equity | 14.3M | 13.4M | 19.6M | 10.4M | 6.96M |
| Cash & Short-term Investments | 21.8M | 20.8M | 25.0M | 11.6M | 8.68M |
| Cash Flow | |||||
| Operating Cash Flow | -7.16M | -9.19M | -8.06M | -11.5M | -8.04M |
| Capital Expenditure | 421K | 288K | 247K | 261K | 151K |
| Free Cash Flow | -7.58M | -9.48M | -8.30M | -11.8M | -8.19M |
| Ratios | |||||
| ROE | -60.7% | -92.2% | -37.6% | -96.7% | -135.3% |
| ROA | -30.4% | -45.2% | -22.1% | -51.1% | -65.5% |
| Net Profit Margin | -2,913.1% | -1,568.4% | -155.7% | -5,728.6% | -1,040.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
VALBIOTIS S.A. EO -10 dividends
VALBIOTIS S.A. EO -10 has not paid dividends in the last 5 fiscal years.
Who owns VALBIOTIS S.A. EO -10
- Insiders 2.57%
- Institutions 1.53%
- Public & others 95.90%
- Shares outstanding 35.5M
- Free float 34.8M
VALBIOTIS S.A. EO -10 company profile
- Company name
- VALBIOTIS S.A. EO -10
- Ticker
- 8JD.F
- ISIN
- FR0013254851
- Exchange
- Frankfurt Exchange
- Sector
- Consumer Defensive
- Industry
- Biotechnology
- Employees
- 50
- Fiscal year end
- December
- Address
- Rue Paul Vatine, Périgny, France, 17180
- Phone
- 33 5 46 28 62 58
- Website
- valbiotis.com
About VALBIOTIS S.A. EO -10
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Additionally, the company offers e-commerce delivery service in Belgium and Luxembourg. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.
VALBIOTIS S.A. EO -10 management
7- Mr. Sebastien Peltier HDR, Ph.D.Co-Founder, Chairman of the Management Board & CEO · born 1978
- Mr. Stanislas SordetCFO & Member of Management Board
- Mr. Sebastien BessyCOO & Member of the Management Board
- Mr. Pascal Sirvent Ph.D.CSO & Member of the Management Board
- Ms. Murielle CazaubielCMO & Member of the Management Board
- Mr. Sebastien PoncetMember of the Management Board
- Dr. Josep InfestaHead of Global Business Development